Satellite symposium: Antibody-Drug Conjugate Therapies in Locally Advanced (la) and Metastatic Urothelial Carcinoma (mUC)

Bladder cancer is the tenth most common cancer worldwide. Urothelial carcinoma is responsible for over 90% of bladder cancers in Europe. Close to 60% of those diagnosed with urothelial carcinoma will at one point or another be diagnosed with metastatic disease (mUC) which carries an abysmal prognosis of only 5.5%. Drug discoveries in the field of urothelial carcinomas have exploded in the last decade which has led to the breakthrough development of immune checkpoint inhibitors (ICIs). Programmed cell death-1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) inhibitors have shown increased clinical treatment. Still, many mUC patients still relapse following both platinum-based and immunotherapy-based regimens. This large clinical need for mUC patients, has led to the recent development and use of antibody-drug conjugates (ADCs). ADCs are small monoclonal antibodies that are connected to an anti cancer cytotoxic molecule. This allows the monoclonal antibody portion of the ADC to selectively deliver an anti cancer agent to a tumour cell that expresses a specific antigen. ADCs allow for conventional cytotoxic therapies to be renovated into highly effective and specific chemotherapies, potentially enabling synergistic outcomes when combined with immunotherapies. The European Society for Translational Medicine (EUSTM) has identified knowledge gaps in the understanding of ADC clinical trials, combination with immunotherapy and safety and efficacy profiles. This proposed 90-minute virtual satellite symposium will be held at the EUSTM-2023 Congress. The objective of this event is to increase the knowledge and understanding that HCPs have about the antibody drug conjugates (ADC) in treatment of mUC, the important and trail-blazing ADC clinical trials for mUC patients, and their respective safety and efficacy profiles.